AI Stock Memo: GH - Guardant Health - RankAlpha

GH

Rating buyAI Memo

Guardant Health

As of 2026-02-20/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-20 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Clinical readout or regulatory decision for new indication • 2026-09-30

Expected move: -12%

Biggest risk

Slow adoption, reimbursement setbacks, or negative readouts drive repeated guidance cuts and push valuation toward analyst lows.

Invalidation

Break below $55 or thesis failure.

What would change my mind?

Successful scaling of commercial tests and favorable reimbursement lifts revenue and margins toward analyst highs.

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-20

Base target

$114

p=60%

Bull target

$175

p=20%

Bear target

$55

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly results / revenue update
Broader commercial adoption and payer coverage
Successful scaling of commercial tests and favorable reimbursement lifts revenue and margins toward analyst highs.

BearKey bullets

Adverse reimbursement decisions limiting commercial uptake
Disappointing clinical readouts or regulatory delays
Execution risk on margin and cost control

WatchKey bullets

Clinical readout or regulatory decision for new indication

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $114 (p=60%)

Bull/Bear spread: +35% / -58%

Vs latest close: Bull +35% · Base -12% · Bear -58%

Scenario probabilities

Bull Target: $175 (p=20%)Base Target: $114 (p=60%)Bear Target: $55 (p=20%)

Commentary

Sentiment is mixed — analyst targets cluster near the median while the high/low spread is wide, reflecting disagreement on reimbursement and adoption. Near-term focus: results and payer updates; long-term view depends on commercial traction and regulatory clarity.

As of 2026-02-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Successful scaling of commercial tests and favorable reimbursement lifts revenue and margins toward analyst highs.

Bear Case

Slow adoption, reimbursement setbacks, or negative readouts drive repeated guidance cuts and push valuation toward analyst lows.

Drivers

Scannable catalysts and supporting factors

Next quarterly results / revenue update
Broader commercial adoption and payer coverage

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-20Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$113.84

Range (USD)

$55.00 - $175.00

Count

Query: Guardant Health Inc Common (GH) analyst consensus price target high low average

Guardant Health, Inc. (GH) Stock Price, News, Quote & History
Search result #1
Find the latest Guardant Health, Inc. (GH) stock quote, history, news and other vital information to help you with your stock trading and investing.
Open source
Guardant Health (GH) Stock Forecast & Price Target - Investing.com
Search result #2
According to projections from 22 analysts, the average 12-month price target for Guardant Health is 125.24, with a high estimate of 175 and a low estimate of 60 ...
Open source
Guardant Health (GH) Stock Forecast, Price Targets and Analysts ...
Search result #3
The average price target is $132.35 with a high forecast of $175.00 and a low forecast of $105.00. The average price target represents a 24.42% change from the ...
Extracted: $132.35, $175.00, $105.00Open source
What is the current Price Target and Forecast for Guardant Health (GH)
Search result #4
The forecasts range from a low of $105.00 to a high of $175.00. The average price target represents an increase of 19.11% from the last closing price of $107. ...
Extracted: $105.00, $175.00, $107.00Open source
Guardant Health (GH) Stock Forecast & Price Target - MarketBeat
Search result #5
The highest price target for GH is $175.00, while the lowest price target for GH is $55.00. The average price target represents a forecasted upside of 1.01% ...
Extracted: $175.00, $55.00Open source
Guardant Health, Inc. Stock Forecast | GH Price Target & Analyst ...
Search result #6
Based on 30 analysts in the last 3 months, the overall rating is Buy with a 12-month price target of $89.08, representing 0.00% downside from the current ...
Extracted: $89.08Open source

Scenarios

Bull Target (Scenario probability)

$175 / p=20% prob

Base Target (Scenario probability)

$114 / p=60% prob

Bear Target (Scenario probability)

$55 / p=20% prob

Price $130 as of 2026-05-29

Nearest Scenario: Base (∆ 12%)

Targets vs latest close: Bull +35% · Base -12% · Bear -58%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-30
Clinical readout or regulatory decision for new indication
Binary clinical/regulatory outcomes may drive large re-rating; date provided as planning-window end per event-rule.
Prob 30.00% • Move 40.00% • Priced-in 15.00%

Short-term Catalysts

Next few weeks

Next quarterly results / revenue update
2026-05-21
Quarterly results may revise revenue guidance and near-term visibility; market reaction likely focused on diagnostic volumes and margin commentary.
Prob 60% • Move 12% • Priced-in 45%

Long-term Catalysts

Months to a year

Broader commercial adoption and payer coverage
2027-02-20
Expanded payer coverage and international rollout could materially lift recurring revenue over the long horizon; timing assumed per long-window rule.
Prob 35% • Move 60% • Priced-in 25%

Risks

Adverse reimbursement decisions limiting commercial uptake
Disappointing clinical readouts or regulatory delays
Execution risk on margin and cost control
Intense competition pressuring pricing and volume

Peers

Symbol	Summary
EXAS	Exact Sciences — large-scale screening commercialization lessons and payer engagement comparators.
NTRA	Natera — competing cfDNA and oncology assays with similar payer dynamics.
MYGN	Myriad — overlapping clinical channels and commercialization experience in cancer testing.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Guardant Health Inc Common (GH) analyst consensus price target high low average
Analysis date: 2026-02-20